Abstract submitters have been notified of the acceptance/rejection and format of their submission. If you have not received notification by December 22, please contact Be sure to check your spam box.

NOTE: Authors who submit abstracts are not automatically registered for the meeting. In order to participate in the meeting and make their presentations, authors must register for the meeting and cover the costs of hotel and travel.



October 2017

Online abstract submission site opens

December 8, 2017, 11:59 pm PST

Deadline to submit an abstract(s)
Deadline to submit for an award

December 20, 2017

Acceptance/rejection communicated

January 5, 2018

Deadline for Early Bird Registration

February 16, 2018

Deadline for Poster withdrawal

March 26, 2018

Platform PowerPoint presentation deadline

April 10-14, 2018

ACMG Annual Clinical Genetics Meeting, Charlotte, North Carolina




To submit an abstract, the following criteria must be met: 

Research and/or studies must fit into one of the ACMG 2018 Abstract Review Categories.

- Clinical Genetics
- Cancer Genetics
- Molecular Genomics/Exome Sequencing
- Clinical Cytogenetics and Genomics
- Pre-and Perinatal Genetics
- Biochemical/Metabolic Genetics
-Genetic Counseling
- Health Services/Implementation
-Legal and Ethical Issues
- Education
- Therapeutics

 Responsibilities of the First Author/Presenting Author

  • The first author listed for each abstract serves as the presenting author and as the primary contact for all correspondence regarding the abstract, unless otherwise specified under the “Contact Information” section of the online abstract submission system.
  • The presenting author is the First Author and must be one of the co-authors listed on the submitted abstract.
  • The presenting author is responsible for the following:
    • Ensuring that all authors have read the abstract and agreed to be co-authors. Failure to get approval from all authors will result in rejection of the abstract.
    • Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by ACMG.
    • Obtaining all of the conflict-of-interest disclosure and copyright transfer information from co-authors. This information is to be kept on file by the presenting author. If the abstract is accepted for a platform presentation, then the documentation may be requested by the ACMG office for review.
    • If accepted for a platform presentation then the presenting author must forward all correspondence to all co-authors, including ACMG policies and guidelines and the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support for Continuing Medical Education (CME). These documents can be downloaded upon platform acceptance.
  • An individual may be first author (i.e., presenting author) of more than one abstract. If the first author should have multiple accepted posters and has a conflict with the poster presentation schedule, then it is acceptable to designate one of the co- authors to present one of the posters. The abstract number determines the schedule. The number of an abstract cannot be changed.  

Authors’ Consent and Waiver of Claims

  • Each abstract author agrees and certifies that he or she:
    • has read all of the rules and agrees to be bound by them,
    • is responsible for submission of the abstract in accordance with the rules, and
    • waives any and all claims against ACMG and any reviewer arising out of or relating to the abstract submission and review process, including but not limited to peer review and the grading of abstracts.

Abstract Submission Requirements:

  • The abstract must address scientific questions, detail clinical observations, or contain primary scientific data.
  • Authors assign copyright of the abstract to ACMG upon submission, unless one of the authors is a U.S. Federal employee (in such case, ACMG does not hold copyright). This means that the identical abstract may not be republished or submitted to another meeting.
  • All research and studies reported in submitted abstracts that involve human and animal subjects must comply with the guiding principles for experimental procedures found in the Declaration of Helsinki of the World Medical Association.
  • Interim analysis of a prospective randomized clinical trial will be considered only if it is performed as planned in the original protocol and is statistically valid. If your abstract involves interim analysis, use the Interim Analysis of a Clinical Trial section of the abstract form to explain the details of your study. The reviewers will have this information available during their evaluation.
  • No revisions can be made after the abstract submission deadline (December 8, 2017).
  • The presentation at the annual meeting must reflect the submitted abstract. In particular, the abstract title, authorship, and scientific content of the presentation at the annual meeting must match the submitted abstract, although updates on results may be added by December 8, 2017.
  • Abstracts should be written in clear and concise English, so that reviewers can focus solely on the scientific merits of the submission. We encourage non-English-speaking authors to have their abstracts checked for grammar and spelling prior to submission.
  • It is assumed that the presenting author will have adequate command of English to present and to respond to questions. If that is not the case, the authors should choose a poster as their preference.
  • Abstracts can be submitted if:
    • It is unpublished and original
    • Accepted for publication but not yet published
    • Encore presentations are allowed, only if material was previously presented at a non-genetics meeting within the last 6 – 12 months.

Preferred Presentation Format

During submission, submitters must choose the formats in which they would like to present their abstract. The choice must be made at the time of submission and cannot be changed after the review committee has reached its decision.  
Submission format options:

  1. Poster Presentation Only
  2. Platform Presentation Only
  3. Platform or Poster Presentation (abstract is reviewed and if accepted, it will be either as a platform or a poster presentation)

Authors select presentation format for submission (above). Abstracts noted with a preference for poster presentation only will NOT be considered for a platform presentation, regardless of score.

Abstract Review and Selection Process

  • After the submission deadline, all completed and eligible abstracts will be made available to the ACMG Abstract Reviewers for review and scoring, and final decisions will be made by the Abstract Reviewers in late December, 2017.
  • Abstracts will be evaluated and scored solely on their scientific merits.
  • Incomplete abstracts will not be reviewed.
  • The same study must not be submitted as multiple abstracts. Abstracts that are simply different versions of a single study will be rejected.
  • Abstracts will be peer reviewed according to the subject categories. Authors must indicate during online submission the appropriate review category (one only). All category selections will be final. There will be NO re-classification of abstracts after the abstract submission site has been closed. Abstracts submitted to the wrong category are scored in that category and usually fare poorly.
  • All abstracts submitted will be considered eligible for one presentation format as requested: either plenary, platform (scientific session), or poster. 
    • Platform Presentations are formal platform presentations (15 minutes) that include a brief discussion. Of the abstracts selected, four of the highest rated will be featured in a special plenary session.
    • Poster Sessions allow the viewing of a poster illustration of the abstract. Authors are expected to post and remove posters at designated times and to be at their posters to answer questions during the time designated for poster presentations. Poster presentations are assigned as to presenting on Thursday or Friday, April 12th or 13th. This assignment will not be changed and presenters are required to be at their posters during the designated time. Top rated abstracts selected for Poster Presentation will be highlighted in the Exhibit Hall and ACMG Program.

Acceptance/Rejection Notification

  • Notification regarding acceptance or rejection of abstracts will be sent to the presenting author in late December 2017 by email; consequently, an accurate email address is critical. If your abstract is accepted, the email will specify whether it is accepted as platform or poster presentation. If you have not received an email notification by December 22, contact
  • To ensure that you can receive email correspondence from ACMG, please make sure that your email software can receive mail from the and domains. If after completing your submission you don't receive a confirmation email from the abstract system, you must contact your system administrator and make sure that both domains are added to your email address whitelist. Ask your IT department to allow email from ip4:  .
  • The decision of the ACMG Program Committee regarding acceptance and presentation of abstracts is final.
  • Once your abstract has been accepted, we are NOT able to renumber it to accommodate your schedule. So, if your abstract is designated as an odd number poster, we cannot renumber it as an even number to allow you to present on a different day. Posters remain up throughout the meeting. 
    Poster Presentations ODD Numbers 4/12 10:00am-11:30am
    Poster Presentations EVEN Numbers 4/13 10:30am-12:00pm
  • Presenters of accepted posters will also have the option to submit their poster as an ePoster. This is in addition to presenting a printed poster at the meeting. Printed posters should be created in the following dimensions, to comply with ePoster requirements: 42” x 44”     OR     44” x 44” 

Embargo Policy

All accepted abstracts submitted to the ACMG Annual Meeting are embargoed until the first day of the meeting, unless otherwise noted by ACMG. The first author is responsible for conveying this information to all co-authors. For questions regarding the embargo policy, please contact Claudia Barnett, ACMG Education Coordinator.

Abstract Withdrawal

  • Once an abstract is accepted, a written request to withdraw must be submitted no later than February 16, 2018, to if the first author decides to withdraw the abstract for any reason. Abstract withdrawal requests received after the deadline will be considered on a case-by-case basis. 
  • ACMG reserves the right to withdraw abstracts that are in violation of the College’s policies and guidelines, have been deemed scientifically unsound, or have been found to include inaccurate data, etc.

Featured Platform Presentations
The four highest rated abstracts that are reviewed for a platform presentation will be selected for presentation in a general session. All platform presentations are 15 minutes inclusive of audience questions. Typical format is 12 minutes of presentation and 3 minutes of Q&A.

Abstract Awards (Geneticist-in-Training and Genetic Counselor)

David L. Rimoin Inspiring Excellence Award
The ACMG Foundation for Genetic and Genomic Medicine will issue the David L. Rimoin Inspiring Excellence Award given to a selected student, trainee, or junior faculty ACMG member whose abstract submission is chosen as a platform presentation during the 2018 ACMG Annual Clinical Genetics Meeting. In recognition of their selected presentation, The Rimoin Fund covers the travel costs for the recipient to attend the meeting.

Carolyn Mills Lovell Genetic Counselors Award 

The ACMG Foundation for Genetic and Genomic Medicine will be giving the Carolyn Mills Lovell Genetic Counselors Award to the first author of the highest rated genetic counselor abstract submission for the 2018 ACMG Annual Clinical Genetics Meeting. In recognition of their selected presentation, a $1,000 award will be given to the recipient to attend the meeting. 
Abstract Award recipients will be notified if they will receive an award in January 2018. You must attend the meeting and present your abstract to receive your award.

Disclosure: In accordance with the Accreditation Council for Continuing Medical Education and the policy of the American College of Medical Genetics, before their presentations, all Oral Abstract submitters must disclose the existence of any financial interest and/or other relationship(s) they might have with the manufacturer(s) or provider(s) of any commercial product(s) or service(s) to be discussed during their presentation. Any Oral Abstract presenter with a Financial Disclosure/Conflict of Interest will be contacted by the Program Committee for a slide review and must include a disclosure slide at the start of their presentation. The full text of the disclosure will appear on the website as part of the submission process. All submitters must complete this disclosure statement. Disclosures will be included in the on-site Program Guide. 

NOTE: Authors who submit abstracts are not automatically registered for the meeting. In order to participate in the meeting and make their presentations, authors must register for the meeting and cover the costs of hotel and travel.